{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:25:51Z","timestamp":1794489951035,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare and aggressive disease. Recently, focus has shifted toward a more aggressive and multimodal treatment approach. This study aimed to assess the patterns of care and survival for MPM patients in the Netherlands on a nationwide basis.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The records of patients with a diagnosis of MPM from 1993 to 2016 were retrieved from the Dutch Cancer Registry. Data regarding diagnosis, staging, treatment, and survival were extracted. Cox regression analyses and Kaplan\u2013Meier survival curves were used to study overall survival.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 1993 and 2016, MPM was diagnosed for 566 patients. Overall, the prognosis was very poor (24% 1-year survival). The most common morphologic subtype was the epithelioid subtype (88%), followed by the biphasic (8%) and sarcomatoid (4%) subtypes. Surgical treatment has become more common in recent years, which most likely has resulted in improved survival rates. In this study, improved survival was independently associated with hyperthermic intraperitoneal chemotherapy (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.21\u20130.55) and surgery with adjuvant systemic chemotherapy (HR, 0.33; 95% CI, 0.23\u20130.48). Nonetheless, most patients (67%) do not receive any form of anti-cancer treatment.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study indicated that MPM still is a rare and fatal disease. The survival rates in the Netherlands have improved slightly in the past decade, most likely due to more aggressive treatment approaches and increased use of surgery. However, most patients still do not receive cancer-directed treatment. To improve MPM management, and ultimately survival, care should be centralized in expert medical centers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-019-07803-z","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:02:10Z","timestamp":1571252530000},"page":"4222-4228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study"],"prefix":"10.1245","volume":"26","author":[{"given":"Nadine L.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job P.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A. M.","family":"Damhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva V. E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"7803_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5:236.","journal-title":"Ann Transl Med"},{"key":"7803_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985\u2013990.","journal-title":"Ann Oncol"},{"key":"7803_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/oem.51.12.804","volume":"51","author":"R Spirtas","year":"1994","unstructured":"Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804\u201311.","journal-title":"Occup Environ Med"},{"key":"7803_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/030089160308900307","volume":"89","author":"YI Acherman","year":"2003","unstructured":"Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269\u201373.","journal-title":"Tumori"},{"key":"7803_CR5","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560\u20137.","journal-title":"J Clin Oncol"},{"key":"7803_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdl021","volume":"17","author":"P Baas","year":"2006","unstructured":"Baas P, van\u2019t Hullenaar N, Wagenaar J, et al. Occupational asbestos exposure: how to deal with suspected mesothelioma cases: the Dutch approach. Ann Oncol. 2006;17:848\u201352.","journal-title":"Ann Oncol"},{"key":"7803_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.lungcan.2013.01.012","volume":"80","author":"S van der Bij","year":"2013","unstructured":"van der Bij S, Baas P, van de Vijver MJ, de Mol BA, Burgers JA. Legal claims for malignant mesothelioma: dealing with all cases. Lung Cancer. 2013;80:153\u20138.","journal-title":"Lung Cancer"},{"key":"7803_CR8","first-page":"911","volume":"116","author":"HT Planteydt","year":"1972","unstructured":"Planteydt HT. Het mesothelioomregister [the mesothelioma register]. Ned Tijdschr Geneeskd. 1972;116:911\u20132.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"7803_CR9","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","volume":"25","author":"V Verma","year":"2018","unstructured":"Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25:2018\u201326.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canep.2017.10.008","volume":"51","author":"SAS Salo","year":"2017","unstructured":"Salo SAS, Ilonen I, Laaksonen S, Myllarniemi M, Salo JA, Rantanen T. Epidemiology of malignant peritoneal mesothelioma: a population-based study. Cancer Epidemiol. 2017;51:81\u20136.","journal-title":"Cancer Epidemiol"},{"key":"7803_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/1753-6405.12503","volume":"40","author":"MJ Soeberg","year":"2016","unstructured":"Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality, and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972\u20132009. Aust N Z J Public Health. 2016;40:255\u201362.","journal-title":"Aust N Z J Public Health"},{"key":"7803_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/oemed-2015-103309","volume":"73","author":"MJ Soeberg","year":"2016","unstructured":"Soeberg MJ, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982\u20132009. Occup Environ Med. 2016;73:187\u201394.","journal-title":"Occup Environ Med"},{"key":"7803_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10408440903044928","volume":"39","author":"B Price","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576\u201388.","journal-title":"Crit Rev Toxicol"},{"key":"7803_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","volume":"46","author":"S Liu","year":"2014","unstructured":"Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46:604\u20139.","journal-title":"Pathology"},{"key":"7803_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jtcvs.2008.12.045","volume":"138","author":"TD Yan","year":"2009","unstructured":"Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138:619\u201324.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"7803_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.athoracsur.2010.04.110","volume":"90","author":"AS Wolf","year":"2010","unstructured":"Wolf AS, Richards WG, Tilleman TR, et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg. 2010;90:949\u201356; discussion 956.","journal-title":"Ann Thorac Surg"},{"key":"7803_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/modpathol.2009.180","volume":"23","author":"S Klebe","year":"2010","unstructured":"Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470\u20139.","journal-title":"Mod Pathol"},{"key":"7803_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgz004","volume":"40","author":"M Van Gerwen","year":"2019","unstructured":"Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40:529\u201336.","journal-title":"Carcinogenesis"},{"key":"7803_CR19","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","volume":"69","author":"G Pinton","year":"2009","unstructured":"Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69:4598\u2013604.","journal-title":"Cancer Res"},{"key":"7803_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855\u201363.","journal-title":"Cancer"},{"key":"7803_CR21","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947\u201353.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR22","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol"},{"key":"7803_CR23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686\u201393.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","volume":"7","author":"PH Sugarbaker","year":"2018","unstructured":"Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res. 2018;7:599\u2013608.","journal-title":"Transl Lung Cancer Res"},{"key":"7803_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/s10434-008-0219-1","volume":"16","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463\u201372.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093\u2013100.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159\u201365.","journal-title":"Ann Surg Oncol"},{"key":"7803_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779\u201386.","journal-title":"Surgery"},{"key":"7803_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ajim.22768","volume":"60","author":"RL Kradin","year":"2017","unstructured":"Kradin RL, Eng G, Christiani DC. Diffuse peritoneal mesothelioma: a case series of 62 patients including paraoccupational exposures to chrysotile asbestos. Am J Ind Med. 2017;60:963\u20137.","journal-title":"Am J Ind Med"},{"key":"7803_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/jnci\/djj106","volume":"98","author":"YI Baris","year":"2006","unstructured":"Baris YI, Grandjean P. Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite. J Natl Cancer Inst.2006;98:414\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"7803_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135.","journal-title":"Nat Genet"},{"key":"7803_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","volume":"13","author":"H Alakus","year":"2015","unstructured":"Alakus H, Yost SE, Woo B, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122.","journal-title":"J Transl Med"},{"key":"7803_CR33","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/oemed-2017-104298","volume":"74","author":"CO Odgerel","year":"2017","unstructured":"Odgerel CO, Takahashi K, Sorahan T, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74:851\u20138.","journal-title":"Occup Environ Med"},{"key":"7803_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2471\/BLT.13.132118","volume":"92","author":"T Kameda","year":"2014","unstructured":"Kameda T, Takahashi K, Kim R, et al. Asbestos: use, bans, and disease burden in Europe. Bull World Health Organ. 2014;92:790\u20137.","journal-title":"Bull World Health Organ"},{"key":"7803_CR35","doi-asserted-by":"publisher","first-page":"e026779","DOI":"10.1136\/bmjopen-2018-026779","volume":"9","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts J, Madsen EVE. Adjuvant dendritic cell-based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single-centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open. 2019;9:e026779.","journal-title":"BMJ Open"},{"key":"7803_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","volume":"24","author":"J Aerts","year":"2018","unstructured":"Aerts J, de Goeje PL, Cornelissen R, et al. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res. 2018;24:766\u201376.","journal-title":"Clin Cancer Res"},{"key":"7803_CR37","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","volume":"193","author":"R Cornelissen","year":"2016","unstructured":"Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016;193:1023\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"7803_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","volume":"181","author":"JP Hegmans","year":"2010","unstructured":"Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181:1383\u201390.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07803-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:11:20Z","timestamp":1602717080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07803-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7803"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07803-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}